| Health Care Technology Industry | Healthcare Sector | Mr. Yann M. Duchesne CEO | XPAR Exchange | FR0004197747 ISIN |
| FR Country | 28 Employees | - Last Dividend | - Last Split | - IPO Date |
Founded in 2004 and based in Malakoff, France, Theraclion SA is a pioneer in the field of echotherapy solutions, utilizing high-intensity focused ultrasound (HIFU) technology. The company specializes in developing innovative, non-invasive medical devices aimed at improving treatment options for various conditions. With a focus on robotic technology, Theraclion's products offer precision and ease of use for both medical practitioners and patients, aligning with the modern healthcare objective of enhancing treatment outcomes while minimizing patient discomfort and recovery time.
SONOVEIN is Theraclion's pioneering robotic solution designed for the non-invasive echotherapy treatment of varicose veins. Leveraging high-intensity focused ultrasound, SONOVEIN provides a cutting-edge alternative to traditional surgical procedures, offering patients a less painful and faster recovery treatment option, without the need for incisions or general anesthesia.
ECHOPULSE represents Theraclion’s advanced, robotic, and non-invasive solution aimed at the echotherapy treatment of thyroid nodules and breast fibroadenoma. Through its precise ultrasound technology, ECHOPULSE targets and treats affected tissues with minimal impact on surrounding healthy tissues, which contributes to quicker patient recovery and less post-operative complications compared to conventional surgical methods.
The EPack is a specially designed disposable that attaches to Theraclion's devices prior to the treatment. It serves a dual purpose: protecting the patient's skin during the echotherapy procedure and optimizing the quality of the ultrasound image. The usage of EPack is indicative of Theraclion's commitment to patient safety and the maximization of treatment efficacy through technological innovation.